Background: Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease
characterized by progressive swelling and stiffness in the joints. Mavrilimumab is a human monoclonal
antibody that may block the autoimmune mechanism of the antibodies causing RA.
Objective: We aim to assess the safety and efficacy of Mavrilimumab in treating rheumatoid arthritis.
Methods: We conducted an online search using PubMed, Scopus, Web of Science, and Cochrane
CENTRAL till June 2019, and updated the search in May 2020, using relevant keywords. We
screened studies for eligibility. Data were extracted from eligible studies and pooled as Risk ratio
(RR) with a 95% confidence interval (CI), using Review Manager software (ver.3.5).
Results: Five studies (with 1145 patients) were eligible to our criteria. Pooled result from three
trials showed a significant reduction in Disease Activity Score 28 based on C-reactive protein
(DAS28-CRP) remission < 2.6 after 12 weeks (RR = 3.31, 95% CI [1.53, 7.18], P = 0.002), American
College of Rheumatology (ACR) 20, after 12 weeks (RR = 2.38, 95% CI [1.80, 3.16], P <
0.00001), ACR 50, after 12 weeks (RR = 2.93, 95% CI [1.67, 5.15], P = 0.0002), ACR 70, after 12
weeks (RR = 4.90, 95% CI [1.60, 15.00], P = 0.005). Mavrilimumab not associated with a significant
adverse event (RR = 1.22, 95% CI [0.89, 1.68], P = 0.22).
Conclusion: We found that subcutaneous Mavrilimumab was effective and well-tolerating in treating
RA patients, with no significant adverse events.